MedTrace Logo

Pharmaco(Epi)Genetic, Proteomic, and Microbiomic Study of Obsessive-Compulsive Disorder

NCT02431845 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2024-12-27

No results posted yet for this study

Summary

The purpose of this study is to determine whether pharmaco(epi)genetic study predict selective serotonin reuptake inhibitor (SSRI) responsiveness in advance before the appearance of the drug effect until 4 months(16 weeks), 6 months, and 1 year after administration of SSRIs.

Conditions

  • Obsessive-Compulsive Disorder

Interventions

DRUG

SSRIs

usual dose SSRI for obsessive-compulsive disorder, i.e. fluoxetine 40\~80 mg dose equivalents

Sponsors & Collaborators

  • Severance Hospital

    lead OTHER

Principal Investigators

  • Se Joo Kim, M.D. · Professor, Department of Psychiactry, Yonsei Univ. College of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-01
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02431845 on ClinicalTrials.gov